Video

Belimumab With Standard Therapy Proves Beneficial in Lupus Nephritis

In today’s one-on-one interview, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

CITATION: Richard Furie, M.D., Brad H. Rovin, M.D., Frédéric Houssiau, M.D., Ph.D., et al. "Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis," New England Journal of Medicine. Sept. 17, 2020. DOI: 10.1056/NEJMoa2001180

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Related Content
CAR-T Therapy Gets Fast Tracked for Relapsed/Refractory SLE
December 3rd 2024

CAR-T Therapy Gets Fast Tracked for Relapsed/Refractory SLE

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Laure Gossec, MD, PhD, Professor of Rheumatology, Pitié-Salpêtrière Hospital and Sorbonne University - Pierre et Marie Curie Campus, Paris, France.
Published: November 30th 2024 | Updated: November 30th 2024

Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Zahi Touma, MD, PhD, director, Toronto Lupus Program and Associate Professor of medicine, department of medicine, division of rheumatology, Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto
November 27th 2024

Anifrolumab Delayed Onset of Organ Damage in Patients With SLE

Victoria Johnson
Lihi Eder, MD, associate professor of medicine, Women’s College Hospital and University of Toronto, Canada
November 26th 2024

Guselkumab Similarly Efficacious Among Male, Female Patients With PsA

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.